Epic Bio
South San Francisco, United States · Founded 2018 · $123.0M raised
- Headquarters
- South San Francisco, California
- Employees
- 11–50
- Founded
- 2018
- Business Model
- B2B
- Website
- epicrispr.com
- Total Funding
- $123.0M
- Last Round
- $68.0M Series BMar 2025
- Rounds
- 2
About
Epic Bio (now Epicrispr Biotechnologies) develops epigenetic gene therapies using ultracompact CRISPR tools to modulate gene expression without cutting DNA.
Summary
Epic Bio is a Biotech company based in South San Francisco, United States, founded in 2018. It has raised $123.0M in total across 2 rounds, most recently a $68.0M Series B round in Mar 2025. Investors include Ally Bridge Group, Horizons Ventures and Solve FSHD.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Mar 2025
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
Clinical-stage biotechnology company developing T-cell engager therapeutics for autoimmune and in...